3[1]Nishikawa H,Miura S,Zhang B,et al.Statins induce the regression of left ventricular mass in patients with angina[J].Circ J,2004,68:121-125.
4[2]Luo JD,Zhang WW,Zhang GP,et al.Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis[J].Clin Exp Pharmacol physiol,1999,26:903-908.
5[6]Sun Y,Zhang J,Zhang JQ,et al.Local angiotensin Ⅱ and transforming growth factor betal in renal fibrosis of rats[J].Hypertens,2000,35:1078-1084.
6[7]Sun Y,Zhang JQ,Zhang J,et al.Angiotensin transforming growth factor betal and repair in the infarcted heart[J].Mol Cell Cardio,1998,30:1559-1569.
7[8]Hein S,Arnon E,Kostin S,et al.Progression from compensated hypertrophy to failure in the pressure overloaded human heart.Structural deterioration and compensatory mechanisms[J].Circulation,2003,107:984-991.
8[9]Rosenkranz S,Flesch M,Amann K,et al.Alterations of β-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGFβ1[J].Am J Physiol Heart Circ Physiol,2002,283:1253-1262.
9[10]Tomasek JJ,Gabbiani G,Hinz B,et al.Myofibroblasts and mechano-regulation of connective tissue remodelling[J].Nat Rev Mol Cell Biol,2002,3:349-363.
10[11]Pinto YM,PintoSietsma SJ,Philipp T,et al.Reduction in left ventricular messenger RNA for transforming growth factor β1 attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR (mRen2) 27 Rat[J].Hypertens,2000,36:747-754.
2Hunt SA,Abraham WT,Chin MH,et al.ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure):developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation:endorsed by the Heart Rhythm Society[J].Circulation,2005,112(12):e154-e235.
3Dickstein K,Cohen-Solal A,Filippatos G,et al.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008:the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association of the ESC(HFA)and endorsed by the European Society of Intensive Care Medicine(ESICM)[J].Eur Heart J,2008,29(19):2388-2442.
4Dinh W,Füth R,Lankisch M,et al.Growth-differentiation factor-15:a novel biomarker in patients with diastolic dysfunction?[J].Arq Bras Cardiol,2011,97(1):65-75.
5Bootcov MR,Bauskin AR,Valenzuela SM,et al.MIC-1,a novel macrophage inhibitory cytokine,is a divergent member of the TGF-beta superfamily[J].Proc Natl Acad Sci U S A,1997,94(21):11514-11519.
7Kempf T,von Haehling S,Peter T,et al.Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure[J].J Am Coll Cardiol,2007,50(11):1054-1060.
8Anand IS,Kempf T,Rector TS,et al.Serial measurement of growth-differentiation factor-15 in heart failure:relation to disease severity and prognosis in the Valsartan Heart Failure Trial[J].Circulation.2010,122(14):1387-1395.
9Baessler A,Strack C,Rousseva E,et al.Growth-differentiation factor-15 improves reclassification for the diagnosis of heart failure with normal ejection fraction in morbid obesity[J].Eur J Heart Fail,2012,14(11):1240-1248.
10Xu J,Kimball TR,Lorenz JN,et al.GDF15/MIC-1 functions as a protective antihypertrophic factor released from the myocardium in association with Smad protein activation[J].Circ Res,2006,98(3):342-350.
